Targeting the PI3K signaling pathway in KRAS mutant colon cancer

Metastatic colorectal cancer (CRC) patients with v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are resistant to monoclonal antibody that targets the epidermal growth factor receptor such as cetuximab. BKM120 targets phosphatidylinositide‐3‐kinase (PIK3CA), but it is unknown w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Suntaek, Kim, SoYoung, Kim, Hye Youn, Kang, Myunghee, Jang, Ho Hee, Lee, Won‐Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735771/
https://www.ncbi.nlm.nih.gov/pubmed/26715098
http://dx.doi.org/10.1002/cam4.591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735771/
https://www.ncbi.nlm.nih.gov/pubmed/26715098
http://dx.doi.org/10.1002/cam4.591

Ejemplares similares